Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer
Source abstract
Abstract
Immune checkpoint blockade (ICB) has shown great promise in treating various advanced malignancies including triple-negative breast cancer (TNBC). However, only limited number of patients could benefit from it due to the low immune response rate caused by insufficient matured dendritic cells (DCs) and inadequate tumor infiltration of cytotoxic T lymphocytes (CTLs). Here, we report a combination therapeutic strategy which integrates STING pathway activation, hypoxia relief and sonodynamic therapy (SDT) with anti-PD-L1 therapy to improve the therapeutic outcome. The synthesized nanodroplet consisted of a O2-filled Perfluorohexane (PFH) core and a lipid membrane carrying sonosensitizer IR-780 and STING agonist Vadimezan (DMXAAs). It released O2 inside the hypoxic tumor tissue, thereby enhancing SDT which relied on O2 to generate cytotoxic reactive oxygen species (ROS). The co-delivered STING agonist DMXAAs promoted the maturation and tumor antigen cross-presenting of DCs for priming of CTLs. Moreover, SDT induced immunogenic cell death (ICD) of tumor to release abundant tumor-associated antigens, which increased tumor immunogenicity to promote tumor infiltration of CTLs. Consequently, not only a robust adaptive immune response was elicited but also the immunologically "cold" TNBC was turned "hot" to enable a potent anti-PD-L1 therapy. The nanodroplet demonstrated strong efficacy to systemically suppress TNBC growth and mimic distant tumor in vivo. STATEMENT OF SIGNIFICANCE: Only a limited number of triple-negative breast cancer (TNBC) patients can benefit from immune checkpoint blockade therapy due to its low immune response rate caused by insufficient matured DCs and inadequate tumor infiltration of cytotoxic T lymphocytes (CTLs). Interestingly, compelling evidence has shown that sonodynamic therapy (SDT) not only directly kills cancer cells but also elicits immunogenic cell death (ICD), which promotes tumor infiltration of cytotoxic T lymphocytes to transform an immunosuppressive "cold" tumor into a "hot" one. However, the hypoxic tumor microenvironment severely restricts the therapeutic efficiency of SDT, wherein, oxygen is indispensable in the process of ROS generation. Here, we report an O2-filled nanodroplet-enhanced sonodynamic therapy that significantly potentiated immune checkpoint blockade for systemic suppression of TNBC.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Stress, Anesthesia, and Immune Response · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Global trends in immunotherapy research on breast cancer over the past 10 years10.1155/2020/4708394 ↗
2. A biomimetic 3D model of hypoxia-driven cancer progression10.1038/s41598-019-48701-4 ↗
3. Triple-negative breast cancer therapeutic resistance: where is the Achilles' heel10.1016/j.canlet.2020.10.016 ↗
4. Advancing immunotherapy for early-stage triple-negative breast cancer10.1016/S0140-6736(20)31962-0 ↗
5. Benefit in patients with PD-L1-positive TNBC
6. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer10.1016/j.ccell.2021.09.010 ↗
7. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma10.1158/1078-0432.CCR-17-2267 ↗
8. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications10.1038/s41423-020-0488-6 ↗
9. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment10.1016/j.semcancer.2019.08.002 ↗
10. Recent advances in nanomaterial-assisted combinational sonodynamic cancer therapy10.1002/adma.202003214 ↗
11. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death10.1038/s41467-019-11269-8 ↗
12. Fluorine assembly nanocluster breaks the shackles of immunosuppression to turn the cold tumor hot10.1073/pnas.2011297117 ↗
13. Turning cold tumors hot by blocking TGF-beta10.1016/j.trecan.2018.03.005 ↗
14. Necroptosis-inducible polymeric nanobubbles for enhanced cancer sonoimmunotherapy
15. Micro/nanoparticle-augmented sonodynamic therapy (SDT): breaking the depth shallow of photoactivation10.1002/adma.201602012 ↗
16. Microbubble-sonosensitiser conjugates as therapeutics in sonodynamic therapy10.1039/c2cc33913g ↗
17. Multifunctional mesoporous composite nanocapsules for highly efficient MRI-guided high-intensity focused ultrasound cancer surgery10.1002/anie.201106180 ↗
18. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours10.1016/j.jconrel.2015.02.004 ↗
19. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle10.1016/j.biomaterials.2015.11.033 ↗
20. Targeted, triggered drug delivery to tumor and biofilm microenvironments10.2217/nnm-2016-0014 ↗
21. Targeting hypoxia in cancer therapy10.1038/nrc3064 ↗
22. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche10.1016/j.cell.2016.07.032 ↗
23. A hybrid semiconducting organosilica-based O2 nanoeconomizer for on-demand synergistic photothermally boosted radiotherapy10.1038/s41467-020-20860-3 ↗
24. Reactive oxygen species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
25. Photochemistry of singlet oxygen sensor green10.1021/jp406638g ↗
26. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice10.1038/s41467-019-09760-3 ↗
27. Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics10.1152/japplphysiol.90995.2008 ↗
28. Ultrasonic cavitation-assisted and acid-activated transcytosis of liposomes for universal active tumor penetration10.1002/adfm.202102786 ↗
29. Ultrasound-enhanced penetration of topical riboflavin into the corneal stroma10.1167/iovs.13-12133 ↗
30. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
31. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer10.1021/acs.nanolett.0c01140 ↗
32. Cancer immunoediting: from immunosurveillance to tumor escape10.1038/ni1102-991 ↗
33. Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma10.1186/s40425-016-0129-x ↗
34. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy10.1158/2159-8290.CD-13-0985 ↗
35. Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy10.1016/j.biomaterials.2020.120636 ↗
36. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses10.4049/jimmunol.180.10.6868 ↗
37. The TNF cytokine family: one track in a road paved by many10.1016/j.cyto.2013.05.027 ↗
38. Cytokines in cancer immunotherapy10.3390/cancers3043856 ↗
39. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy10.1097/CJI.0b013e31827806e6 ↗
40. T-cell memory differentiation: insights from transcriptional signatures and epigenetics10.1111/imm.12074 ↗